ASH 2022 | Efficacy of ibrexafungerp for treating fungal infections in patients with AML
Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the efficacy of the novel triterpenoid inhibitor ibrexafungerp, to treat fungal infections in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Dr Zucenka discusses risk factors for the development of fungal infections in these patients and explains real-world data showing efficacy of ibrexafungerp in these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy, Honoraria, Other: Travel Expenses; Astellas: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy
